Sterneck Capital Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 75.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 66,932 shares of the biopharmaceutical company’s stock after buying an additional 28,767 shares during the quarter. Gilead Sciences comprises 2.7% of Sterneck Capital Management LLC’s investment portfolio, making the stock its 6th biggest holding. Sterneck Capital Management LLC’s holdings in Gilead Sciences were worth $4,546,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in GILD. Harel Insurance Investments & Financial Services Ltd. grew its stake in Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. grew its stake in shares of Gilead Sciences by 19.4% in the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 267 shares during the last quarter. Penserra Capital Management LLC grew its stake in shares of Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the last quarter. Webster Bank N. A. grew its stake in shares of Gilead Sciences by 51.7% in the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares during the last quarter. Finally, Cohen Capital Management Inc. purchased a new position in shares of Gilead Sciences in the 1st quarter valued at approximately $157,000. Hedge funds and other institutional investors own 74.05% of the company’s stock.
Gilead Sciences, Inc. (GILD) traded up 0.09% during midday trading on Friday, reaching $82.36. The company’s stock had a trading volume of 12,401,948 shares. The firm has a market capitalization of $107.56 billion, a price-to-earnings ratio of 8.94 and a beta of 1.19. The stock’s 50-day moving average price is $77.16 and its 200-day moving average price is $70.20. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.08 EPS. Analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.
Several research analysts have weighed in on GILD shares. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price on the stock in a research note on Wednesday, September 6th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, July 27th. ValuEngine cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $82.00 price target (up from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Eleven research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $83.79.
In other news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders sold a total of 466,819 shares of company stock valued at $36,740,240 in the last three months. Insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.truebluetribune.com/2017/09/17/sterneck-capital-management-llc-raises-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.